ASC36o / Ascletis - LARVOL DELTA

Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity (PRNewswire) - "The Phase I study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ASC36 following single and multiple ascending oral doses in 86 participants with obesity (body mass index (BMI) ≥ 30.0 kg/m²) or overweight (BMI ≥ 27.0 kg/m²)."

Trial status • Obesity